List view / Grid view

Regs & Legs

 

Kymab secures $100 million Series C funding

1 December 2016 | By Niamh Louise Marriott, Digital Editor

The funds will enable Kymab to advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies, with clinical development in 2017...

Send this to a friend